Patients with chronic kidney disease in my country are as high as 120 million, and urgently need to reduce the risk of progress in patients

Chronic kidney disease (CKD) is a serious disease. Patient's renal function decreases, and it is usually related to the increase in risk of heart disease or stroke. According to statistics, the disease affects nearly 850 million people around the world. In my country, as high as 120 million patients with chronic kidney disease.

The renal function of patients with chronic kidney disease has decreased, and the EGFR is reduced or kidney damage or both is marked by both, and it lasts for more than three months. The most common disease of chronic kidney disease is significantly increased due to diabetes, hypertension, and glomerular nephritis, and the risk of complications and cardiovascular events such as cardiovascular failure and cardiovascular incidents have increased significantly.

It should be emphasized that once the patient's patient enters the worst stage of chronic kidney disease, that is, the end -end renal disease (ESKD), its kidney is severely damaged, and the kidney function worsening is performed. It can only maintain life through dialysis or kidney transplantation. Most patients with chronic kidney disease will die due to cardiovascular disease before they are progressing until the end of the end. A few days ago, Daglie's net chronic kidney disease indication was approved in China, which was used to reduce the risk of progressive risk of adult patients with adult patients with adult patients with adults. The risk of hospitalization due to heart failure is the first SGLT2 inhibitor approved in China to treat adult chronic kidney disease.

It is understood that the approval of the China National Drug Administration is a positive result based on the DAPA-CKD III test. This is a clinical study of international multi-centers, random, double-blindness, and placebo-controlled comparison, and 4304 patients with chronic kidney disease with chronic kidney diseases that are combined or not combined with type 2 diabetes. DAPA-CKD III test shows that for patients with increased urinary albumin in the 2-4 stage of chronic kidney disease, the standard therapy (SOC) based on the use of vascular tension enzyme inhibitors or vascular tension receptor blockers (SOC) Compared with the placebo, Dagli can make the main endpoint composed of renal function worsening, end -stage renal disease, cardiovascular or nephropathy death by 39%. Compared with the placebo, Daglie Jing can significantly reduce the comparative risk of death by patients with chronic kidney disease by 31%. Hou Fanfan, a member of the DAPA-CKD Research Executive Committee, an academician of the Chinese Academy of Sciences, and director of the Nephrology Department of Southern Medical University in Southern Medical University, said that based on the pioneering results of DAPA-CKD research, Dag Ling became the first approved in China for the treatment of chronic kidneys SGLT2 inhibitor for disease. The results of this milestone have brought new hope to patients with 120 million chronic kidney disease in China.

In addition, experts reminded that the diagnosis rate of chronic kidney disease is very low, and up to 90%of patients do not know that they have this disease and urgently need to pay attention. (Guangming Daily All Media Reporter Tian Yating)

- END -